One of the biggest threats facing humanity is antibiotic resistance, which research has found adds $20 – $35bn in health care costs annually in America. Not only is this a financial burden for the economy, multidrug-resistant infections kill over 30,000 people every year in Europe (source: statnews.com)
The problem of developing and commercialising novel antibiotics whilst making a return for investors at the same time continues to be a big issue in the industry. Organisations considering an investment in novel anti-infectives face considerable commercial headwinds even though there's an obvious and urgent need.
This year’s Superbugs & Superdrugs event aims to address these issues by hosting a two-day international gathering of senior industry experts, scientific pioneers, and academics sharing their valuable thoughts and perspectives on the subject.
The brochure is available to download on the website, with the full program of presentations and the official speaker line-up. Interested parties can keep up to date with the latest conference news and learn more about the event at http://www.superbugssuperdrugs.com/1888press .
SMi are delighted to welcome this year’s confirmed attendees at the two-day event, including: PSI CRO AG, Fundeni Clinical Institute, Aelin Therapeutics, ACS Dobfar SpA, Destiny Pharma, Walter Reed Army Institute of Research, AMR Centre, Meiji Seika Pharma Co. Ltd., Akthelia Pharmaceuticals, Aberdeen University and Grampian University Hospitals, University of North Texas Health Science Center, LifeArc, and many more.
Attendees of this event can also participate in the interactive post-conference workshops on 20th March 2019. SMi are pleased to have Mahmoud Ghannoum, Director of Center for Medical Mycology, Case Western Reserve University, who will be leading a workshop on Understanding the complexity of the Microbiome and how to navigate it. In addition, there is a workshop on Understanding PK/PD in Antimicrobial Research led by William Hope Professor of Therapeutics and Infectious Diseases, University of Liverpool.
The two-day conference will host a diverse gathering of policy makers and economists, in addition to big pharmas and biotechs, who will discuss incentives, partnerships, regulations and new policies. Industry experts and scientific pioneers are set to present on their research advances and clinical data, as well as alternatives to antibiotics, such as monoclonal antibodies and antimicrobial peptides.
There is an Early Bird offer available until 31/01/19, register today to save £100 at http://www.superbugssuperdrugs.com/1888press .
Superbugs & Superdrugs
18th & 19th March 2019
Holiday Inn Kensington Forum, London, UK
Follow us on Twitter ( @ ) SMIPHARM
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Powered by WPeMatico